Beijing Konruns Pharmaceutical is a leading high-tech pharmaceutical company that was founded in 2003. With a core mission of using life science to care for human health, the company has spent over a decade dedicated to innovative drug research and development. They specialize in creating new and unique medications that effectively treat various conditions.

One of their notable offerings is the 密盖息® series, which includes injection and nasal spray medications. These products, such as 密盖息®(鲑降钙素注射液) and 密盖息®(鲑降钙素鼻用喷雾剂), are designed to suppress the activity of osteoclasts, reducing bone loss and increasing bone density. They also provide dual pain relief mechanisms and offer solutions for treating osteoporosis, osteoporotic pain, and preventing acute bone loss.

Beijing Konruns Pharmaceutical has become a well-established company in the pharmaceutical industry, focusing on research, production, and marketing to ensure the highest quality medications. In 2018, they successfully went public on the Shanghai Stock Exchange (stock code: 603590). Their dedication to innovation and commitment to improving human health solidify their reputation as a trusted brand